Return to CBI Antibody Core Home Page
  Return to biothreat/emerging pathogens list
    Return to malaria parasite (malaria (P. falciparum)) ( Plasmodium falciparum ) list


malaria parasite (malaria (P. falciparum)) ( Plasmodium falciparum )
ATP-dependent phosphofructokinase (K-like)


Antibody Name/Abbreviation: K-like (ATP-dept. phfr)
CBI Antibody Core Code: A0482

"Lot" Number: 1 Position: 100(1471-1570)
% Identical Homology of Target to Mouse Protein: 33% (NP_035346.2| protein tyrosine phosphatase, receptor type, O)
Molecular Weight of fusion protein: N.A. KDa

Target sequence used to make this antibody:
IAVENDLLNYVTSIKHLNLNKQNWSSSLYPGIYFINNKDD
KGHFNEYPSVAPVPISMKSSQMATMKHNANTWAYSDSYIF
VGPVQYSVNPDNLGYSSYIF






Sequence Name: ATP-dependent phosphofructokinase (K-like)
Full name: phosphofructokinase-like protein
UniGene Number: N.A.
Accession Number: PF11_0294
Source organism: malaria parasite (malaria (P. falciparum)) ( Plasmodium falciparum )
Full length size (aa): 1570
NCBI information page: click here

Full length sequence:
MDIENSKKHLSELQEERRRHKITLPDMFKRKVLIKEENNDTYEKNLETKN
DMCYSLNRSDDEKEYLKMKFPNIINNPIIKLYTDPYYTIHMSDKKMNTTD
SINTSMDMSSYNYTTNSFMKEMINMYKPHEKLNIGILFTGQQTPGGHNII
CGVFDCLKKKNKKNTLYGFMNGFQGMLKYNFMELKNEYISMFRNSGGFDM
IKSSDIQIINEDQKKKCFKICRQLNLNGLVIIGDVSGNKSTAILSEYFET
VYKITNEKIKSQELKEKNKEETKCKQDGEKNEKEEQQNEQDDEKNKEQQK
CKQDDEKNKEQQNEQRDDEQNKEQQKCKQDDEQNKEQQNEQRDDEQINME
DNNNICEILKNYVQEDKIYKPYNIIDNNKTCVSNENKSNNNIPYDNIQSY
NMSYDNISTYDFTYDNISDISDEEINKKYPKKNKSFVKTSIVSAPTCVYN
EMKNKYIECSLGFDTTIFSYCQYISYLITHIQTYLQGYHFIKVMGNSSSH
IALECFLQTKVNIILVTEEIKKNNLTLDQIIQFIVDVIQNRYKKYHKNYG
IVIIPDGILKKITQFKKLVTSIIHIKTKFIENKINILTDLQNILSKHLIK
EQQEFFKTLPDFFQIQLLEEICSQQFHYARLSTELLLTHLVKKKLEERQI
NDLEFHTHSYGKEVTCSLPTNFDCAYSYILGFSCVEMLQHKYNGYMCVIK
KLKNLLLNVNDIEILGIPLCHIMKIKKKNKNVAQINIVEQVKSAGEKKKK
IEEKDNPQEIKENGKINKAEKPTKKNKTEKKDKVTKKDKTSKKDKNNTTD
RVKKSSSNIQNDNVNKKDDALTNDLCEPTDSTTNNQNKNALVIRNDPFEE
FFIKRTKVNLKDDAYFIKYKKYRYMYLYEDHYRVLTGIQYEHNFCIDYDD
KSLKFRNKLNSTLSSNDYITIKPNNIFSKINFTISGLTKEYFNKKEHNEE
KSSMTQNNILQNGVILQNNNTYKFNYCKHSSMLSEIEKMLTASAIKFNTI
LIRHNTRITYINNNFFNKLYTISFIHIPKIKDFYILQDNQFHLKQNYRNV
TCPKNVGVVLLSHCTPGTNNILVGLHQRLSINNFKLIGFIKGLKGLLNND
ICLINDNNLKTSINIGGFPLLGVHIQYEKKTNDDQILHIHDLIKENNISK
IIKSCKNNNITNLVFIGDEKVITLMNILNDIFINKDVNIKIVSIPISLYN
SFDKNLIECSIGYHSMVRHISDIISNVQSNCLNINTYYYFIKIHTNISSS
LILSVQLQTHCNICYIGESLNNQLTSLHTVIENISLIIIERINRMKYYGV
ILFSSNLIYYINDFHELCKDVDENIKNVQEIDEIVKNDILPERFQKILKK
ESVDLLNLLTESMKDKLLRKEKRENEDIDSNFEVMLINEIKKYIQNLMEK
SKQNKELYCYKKHMNTISSPINVKNIKVYSDIDYILHFQTLIKVIDREIN
CFFPTHFDNSLAFSHGLLAGIAVENDLLNYVTSIKHLNLNKQNWSSSLYP
GIYFINNKDDKGHFNEYPSVAPVPISMKSSQMATMKHNANTWAYSDSYIF
VGPVQYSVNPDNLGYSSYIF





Questions? Click here for answers.


© Monday, February 16, 2009 by the CBI Antibody Core and the Center for Biomedical Inventions, University of Texas Southwestern Medical School.